Search Results - "McWhorter, Laura T."

Lifestyle Factors and Duration of Androgen Deprivation Affect Bone Mineral Density of Patients with Prostate Cancer During First Year of Therapy by Ryan, Christopher W, Huo, Dezheng, Stallings, James W, Davis, Ronald L, Beer, Tomasz M, McWhorter, Laura T

“…Objectives Androgen deprivation therapy (ADT) is associated with loss of bone mineral density (BMD) and increased fracture risk. We sought to examine the…”
Get full text

Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases by Polascik, Thomas J., Given, Robert W., Metzger, Charles, Julian, Sydney R., Vestal, James C., Karlin, Gary S., Barkley, Craig S., Bilhartz, David L., McWhorter, Laura T., Lacerna, Leo V.

“…To evaluate the efficacy and safety of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases who were…”
Get full text

Utility of pharmacodynamic measures for assessing the oral bioavailability of peptides. 1. Administration of recombinant salmon calcitonin in rats by Sinko, P J, Smith, C L, McWhorter, L T, Stern, W, Wagner, E, Gilligan, J P

“…Salmon calcitonin (sCT) is a therapeutic peptide used in the treatment of Paget's Disease, postmenopausal osteoporosis, and hypercalcemia due to malignancy. In…”
Get more information

Biopharmaceutical approaches for developing and assessing oral peptide delivery strategies and systems : In vitro permeability and in vivo oral absorption of salmon calcitonin (sCT) by SINKO, P. J, LEE, Y.-H, FALZONE, L. M, MCWHORTER, L. T, GILLIGAN, J. P, STERN, W, MAKHEY, V, LEESMAN, G. D, SUTYAK, J. P, YU, H, PERRY, B, SMITH, C. L, PEIDI HU, WAGNER, E. J

“…To evaluate a biopharmaceutical approach for selecting formulation additives and establishing the performance specifications of an oral peptide delivery system…”
Get full text